Altevogt P - Search Results

1

SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.

Hüser L, Sachindra S, Granados K, Federico A, Larribère L, Novak D, Umansky V, Altevogt P, Utikal J. Hüser L, et al. Among authors: altevogt p. Int J Cancer. 2018 Dec 15;143(12):3131-3142. doi: 10.1002/ijc.31609. Epub 2018 Oct 16. Int J Cancer. 2018. PMID: 29905375 Free article.

2

Targeting SOX2 in anticancer therapy.

Hüser L, Novak D, Umansky V, Altevogt P, Utikal J. Hüser L, et al. Among authors: altevogt p. Expert Opin Ther Targets. 2018 Dec;22(12):983-991. doi: 10.1080/14728222.2018.1538359. Epub 2018 Oct 26. Expert Opin Ther Targets. 2018. PMID: 30366514 Review.

3

SOX2 in development and cancer biology.

Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. Novak D, et al. Among authors: altevogt p. Semin Cancer Biol. 2020 Dec;67(Pt 1):74-82. doi: 10.1016/j.semcancer.2019.08.007. Epub 2019 Aug 11. Semin Cancer Biol. 2020. PMID: 31412296 Free article. Review.

4

Novel insights into the function of CD24: A driving force in cancer.

Altevogt P, Sammar M, Hüser L, Kristiansen G. Altevogt P, et al. Int J Cancer. 2021 Feb 1;148(3):546-559. doi: 10.1002/ijc.33249. Epub 2020 Sep 3. Int J Cancer. 2021. PMID: 32790899 Free article. Review.

5

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.

Hüser L, Kokkaleniou MM, Granados K, Dworacek J, Federico A, Vierthaler M, Novak D, Arkhypov I, Hielscher T, Umansky V, Altevogt P, Utikal J. Hüser L, et al. Among authors: altevogt p. Cancers (Basel). 2020 Dec 14;12(12):3761. doi: 10.3390/cancers12123761. Cancers (Basel). 2020. PMID: 33327495 Free PMC article.

6

Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation.

Altevogt P, Bretz NP, Ridinger J, Utikal J, Umansky V. Altevogt P, et al. Semin Cancer Biol. 2014 Oct;28:51-7. doi: 10.1016/j.semcancer.2014.04.008. Epub 2014 Apr 24. Semin Cancer Biol. 2014. PMID: 24769223 Review.

7

CCR5⁺ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions.

Blattner C, Fleming V, Weber R, Himmelhan B, Altevogt P, Gebhardt C, Schulze TJ, Razon H, Hawila E, Wildbaum G, Utikal J, Karin N, Umansky V. Blattner C, et al. Among authors: altevogt p. Cancer Res. 2018 Jan 1;78(1):157-167. doi: 10.1158/0008-5472.CAN-17-0348. Epub 2017 Oct 31. Cancer Res. 2018. PMID: 29089297

8

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V. Groth C, et al. Among authors: altevogt p. Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413826 Free PMC article. Review.

9

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies.

Hüser L, Altevogt P, Utikal J. Hüser L, et al. Among authors: altevogt p. Oncotarget. 2019 Mar 1;10(18):1662-1663. doi: 10.18632/oncotarget.26718. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899437 Free PMC article. No abstract available.

10

Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.

Fleming V, Hu X, Weller C, Weber R, Groth C, Riester Z, Hüser L, Sun Q, Nagibin V, Kirschning C, Bronte V, Utikal J, Altevogt P, Umansky V. Fleming V, et al. Among authors: altevogt p. Cancer Res. 2019 Sep 15;79(18):4715-4728. doi: 10.1158/0008-5472.CAN-19-0053. Epub 2019 Jul 23. Cancer Res. 2019. PMID: 31337655

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

246 results

Search Page